Study of STP938 in Advanced Solid Tumours
Conditions: Solid Tumor Interventions: Drug: STP938 Sponsors: Step Pharma, SAS Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials
NodThera ’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
BOSTON, MA, March 7, 2024– NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, today announces positive data from its Phase Ib/IIa study... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 7, 2024 Category: Pharmaceuticals Source Type: clinical trials
New clinical study published demonstrates superiority of AI-algorithm guided melanoma diagnosis
STOCKHOLM, March 6, 2024. Results from a prospective, multicentre, clinical trial published today in the peer-reviewed British Journal of Dermatology showed that AI helps significantly improve melanoma detection rates.
The trial, conducted in 37... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 7, 2024 Category: Pharmaceuticals Source Type: clinical trials
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
NEW YORK--(BUSINESS WIRE) Mar 07, 2024 -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada MMED), (the“Company” or“MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 7, 2024 Category: Pharmaceuticals Source Type: clinical trials
BlueRock Therapeutics Phase I Clinical Trial for Bemdaneprocel for Parkinson ’s Disease Continues to Show Positive Trends at 18 Months
Berlin, Germany and Cambridge, MA USA, March 6, 2024– Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today details of 18-month data from... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 6, 2024 Category: Pharmaceuticals Source Type: clinical trials
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
FOSTER CITY, Calif.,& RAHWAY, N.J.--(BUSINESS WIRE) March 06, 2024 -- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 2 clinical study... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 6, 2024 Category: Pharmaceuticals Source Type: clinical trials
Long-Acting HIV Treatment Benefits Adults with Barriers to Daily Pill Taking and Adolescents with Suppressed HIV
March 6, 2024 -- Long-acting, injectable antiretroviral therapy (ART) suppressed HIV replication better than oral ART in people who had previously experienced challenges taking daily oral regimens and was found safe in adolescents with HIV viral... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 6, 2024 Category: Pharmaceuticals Source Type: clinical trials
Semaglutide Reduces Severity of Common Liver Disease in People with HIV
March 5, 2024 -- A weekly injection of semaglutide was safe and reduced the amount of fat in the liver by 31% in people with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD), according to a presentation today at the 2024... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 5, 2024 Category: Pharmaceuticals Source Type: clinical trials
Dapivirine Vaginal Ring and Oral Pre-Exposure Prophylaxis Found Safe for HIV Prevention Throughout Pregnancy
March 5, 2024 -- The monthly dapivirine vaginal ring and daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine were each found to be safe for HIV prevention among cisgender women who started... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 5, 2024 Category: Pharmaceuticals Source Type: clinical trials
Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors
Conditions: Recurrent or Metastatic, Advanced Solid Tumors Interventions: Drug: IMB071703 injection Sponsors: Beijng Immunoah Pharma Tech Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials
A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants
Conditions: Chronic Spontaneous Urticaria Interventions: Biological: LP-003 Dose 1 (Single); Biological: LP-003 Dose 2 (Single); Biological: LP-003 Dose 3 (Single); Biological: LP-003 Dose 4 (Single); Biological: LP-003 Dose 5 (Single); Biological: Placebo (Single); Biological: LP-003 Dose 6 (Multiple); Biological: LP-003 Dose 7 (Multiple); Biological: LP-003 Dose 8 (Multiple); Biological: Placebo (Multiple) Sponsors: Longbio Pharma Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials
A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects
Conditions: Myelodysplastic Syndrome (MDS) Interventions: Biological: LP-001 Dose 1 (Single); Biological: LP-001 Dose 2 (Single); Biological: LP-001 Dose 3 (Single); Biological: LP-001 Dose 4 (Single); Biological: LP-001 Dose 5 (Single); Biological: LP-001 Dose 6 (Single); Biological: Placebo (Single); Biological: LP-001 Dose 7 (Multiple); Biological: LP-001 Dose 8 (Multiple); Biological: Placebo (Multiple) Sponsors: Longbio Pharma Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials
A Study Of TL-925 For The Treatment of AC
Conditions: Allergic Conjunctivitis Interventions: Drug: TL-925; Drug: Placebo Sponsors: Telios Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials
A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants
Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) Interventions: Biological: LP-005 Dose 1 (Single); Biological: LP-005 Dose 2 (Single); Biological: LP-005 Dose 3 (Single); Biological: LP-005 Dose 4 (Single); Biological: LP-005 Dose 5 (Single); Biological: LP-005 Dose 6 (Single); Biological: Placebo (Single); Biological: LP-005 Dose 7 (Multiple); Biological: LP-005 Dose 8 (Multiple); Biological: LP-005 Dose 9 (Multiple); Biological: Placebo (Multiple) Sponsors: Longbio Pharma Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
BOSTON--(BUSINESS WIRE)--Mar. 5, 2024-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 5, 2024 Category: Pharmaceuticals Source Type: clinical trials
